1. Home
  2. POOL vs ABVX Comparison

POOL vs ABVX Comparison

Compare POOL & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pool Corporation

POOL

Pool Corporation

HOLD

Current Price

$208.34

Market Cap

9.5B

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$122.74

Market Cap

10.5B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
POOL
ABVX
Founded
1993
2013
Country
United States
France
Employees
N/A
67
Industry
Industrial Specialties
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
9.5B
10.5B
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
POOL
ABVX
Price
$208.34
$122.74
Analyst Decision
Buy
Buy
Analyst Count
10
12
Target Price
$292.29
$128.42
AVG Volume (30 Days)
878.0K
742.2K
Earning Date
05-22-2026
01-01-0001
Dividend Yield
2.42%
N/A
EPS Growth
N/A
N/A
EPS
10.85
N/A
Revenue
$5,289,396,000.00
N/A
Revenue This Year
$4.51
N/A
Revenue Next Year
$3.98
$0.22
P/E Ratio
$19.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$203.80
$4.77
52 Week High
$345.00
$148.83

Technical Indicators

Market Signals
Indicator
POOL
ABVX
Relative Strength Index (RSI) 33.27 54.76
Support Level N/A $106.37
Resistance Level $227.80 $131.27
Average True Range (ATR) 6.67 5.18
MACD -0.60 0.22
Stochastic Oscillator 20.96 78.89

Price Performance

Historical Comparison
POOL
ABVX

About POOL Pool Corporation

Pool Corp distributes swimming pool supplies and related products. Its products include non-discretionary pool-maintenance products, like chemicals and replacement parts, as well as pool equipment, like packaged pools (kits to build swimming pools), cleaners, filters, heaters, pumps, and lights. Customers include pool builders and remodelers, independent retail stores, and pool repair and service companies.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: